Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,119,093

« Back to Dashboard

Which drugs does patent 7,119,093 protect, and when does it expire?

Patent 7,119,093 protects OFEV and is included in one NDA.

This patent has forty patent family members in thirty-four countries.

Summary for Patent: 7,119,093

Title:3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-an- ilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulpho- nate and the use thereof as a pharmaceutical composition
Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulpho- nate of formula I and the use thereof as a pharmaceutical composition ##STR00001##
Inventor(s): Roth; Gerald J. (Biberach, DE), Linz; Guenter (Mittelbiberach, DE), Sieger; Peter (Mittelbiberach, DE), Rall; Werner (Mittelbiberach, DE), Hilberg; Frank (Wien, AT), Bock; Thomas (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/623,971
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo7,119,093► SubscribeYY
Boehringer Ingelheim
nintedanib esylate
CAPSULE;ORAL205832-002Oct 15, 2014RXYesYes7,119,093► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,119,093

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 33 500Jul 24, 2002

International Patent Family for Patent: 7,119,093

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1527047► Subscribe
Serbia52283► Subscribe
Serbia20050046► Subscribe
Portugal1527047► Subscribe
Poland223758► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus